These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32712317)

  • 1. Inference on an heteroscedastic Gompertz tumor growth model.
    Albano G; Giorno V; Román-Román P; Román-Román S; Serrano-Pérez JJ; Torres-Ruiz F
    Math Biosci; 2020 Oct; 328():108428. PubMed ID: 32712317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the effect of a therapy able to modify both the growth rates in a Gompertz stochastic model.
    Albano G; Giorno V; Román-Román P; Torres-Ruiz F
    Math Biosci; 2013 Sep; 245(1):12-21. PubMed ID: 23347900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating and determining the effect of a therapy on tumor dynamics by means of a modified Gompertz diffusion process.
    Albano G; Giorno V; Román-Román P; Román-Román S; Torres-Ruiz F
    J Theor Biol; 2015 Jan; 364():206-19. PubMed ID: 25242298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling tumor growth in the presence of a therapy with an effect on rate growth and variability by means of a modified Gompertz diffusion process.
    Román-Román P; Román-Román S; Serrano-Pérez JJ; Torres-Ruiz F
    J Theor Biol; 2016 Oct; 407():1-17. PubMed ID: 27449789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inferring the effect of therapy on tumors showing stochastic Gompertzian growth.
    Albano G; Giorno V; Román-Román P; Torres-Ruiz F
    J Theor Biol; 2011 May; 276(1):67-77. PubMed ID: 21295592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inferring the effect of therapies on tumor growth by using diffusion processes.
    Román-Román P; Torres-Ruiz F
    J Theor Biol; 2012 Dec; 314():34-56. PubMed ID: 22906590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A stochastic model of cancer growth subject to an intermittent treatment with combined effects: reduction in tumor size and rise in growth rate.
    Spina S; Giorno V; Román-Román P; Torres-Ruiz F
    Bull Math Biol; 2014 Nov; 76(11):2711-36. PubMed ID: 25344426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
    Shah DK; Veith J; Bernacki RJ; Balthasar JP
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inference on the effect of non homogeneous inputs in Ornstein-Uhlenbeck neuronal modeling.
    Albano G; Giorno V
    Math Biosci Eng; 2019 Oct; 17(1):328-348. PubMed ID: 31731354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
    Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
    Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the therapy effect for a stochastic growth Gompertz-type model.
    Albano G; Giorno V; Román-Román P; Torres-Ruiz F
    Math Biosci; 2012 Feb; 235(2):148-60. PubMed ID: 22142644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer.
    Pimenta L; Dornelas M; Cezana L
    N Engl J Med; 2016 Jun; 374(26):2602-3. PubMed ID: 27355551
    [No Abstract]   [Full Text] [Related]  

  • 15. Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer.
    Narod SA
    N Engl J Med; 2016 Jun; 374(26):2602. PubMed ID: 27355550
    [No Abstract]   [Full Text] [Related]  

  • 16. Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer.
    Chan JK; Brady MF; Monk BJ
    N Engl J Med; 2016 Jun; 374(26):2603-4. PubMed ID: 27355549
    [No Abstract]   [Full Text] [Related]  

  • 17. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors.
    Vaghi C; Rodallec A; Fanciullino R; Ciccolini J; Mochel JP; Mastri M; Poignard C; Ebos JML; Benzekry S
    PLoS Comput Biol; 2020 Feb; 16(2):e1007178. PubMed ID: 32097421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
    Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
    J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study".
    Markman M
    Gynecol Oncol; 2007 Apr; 105(1):279-80; author reply 280-1. PubMed ID: 17291570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.